Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advanced Therapies in Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Primary completion
- Oct 2031
- Countries
- 5
01
Overview
A Phase 2 trial of livmoniplimab, FG-M701 in Crohn's disease, ulcerative colitis (UC), sponsored by AbbVie Inc.. Started Jul 2026; status: recruiting.
02
Drugs
livmoniplimabFG-M701
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07697456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697456.